Forum Topic News
  • Conversation: UK biotech Synairgen reveals promising early results for COVID-19 drug

    • July 21, 2020 10:47 AM BST
      • Post(s)
        538

      UK biotech Synairgen reveals promising early results for COVID-19 drug

      Results from a phase 1 trial of Synairgen’s lead COVID-19 candidate SNG001 demonstrated a significant reduction in the risk of developing severe disease compared to placebo.
      The preliminary positive results are good news for the Southampton, UK-based biotech company, and come only four months after Synairgen announced the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) approved the trial.
      The double-blind, placebo-controlled phase 1 trial of SNG001 recruited 101 hospitalised COVID-19 patients from nine hospital sites across the UK. Synairgen found that treatment with its drug resulted in a 79% lower risk of developing severe disease compare to the control arm.
      Patients who received SNG001 were also more than twice as likely to recover, defined by ‘no limitation of activities’ or ‘no clinical or virological evidence of infection’, over the course of the treatment compared to those taking the placebo. While three patients died after being randomised to receive the placebo, no deaths were observed among those treated with SNG001.
      Read more: http://www.pmlive.com/pharma_news/uk_biotech_synairgen_reveals_promising_early_results_for_covid-19_drug_1345137

Add Reputation

Do you want to add reputation for this member by this post?

or cancel